Naobios, a contract development and manufacturing company that provides bioprocess development and production of clinical batches of virus-based products, announced that it has received a €1.7M grant from the Bill & Melinda Gates Foundation to support vaccine development.
Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.
Naobios has manufactured an Omicron variant SARS-CoV-2 virus, which will be used to conduct a Controlled Human Infection Model (CHIM) study.